Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Intangibles (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Intangibles for 16 consecutive years, with $6.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles fell 19.87% year-over-year to $6.9 million, compared with a TTM value of $6.9 million through Sep 2025, down 19.87%, and an annual FY2025 reading of $6.9 million, down 19.87% over the prior year.
  • Intangibles was $6.9 million for Q3 2025 at Arrowhead Pharmaceuticals, down from $7.3 million in the prior quarter.
  • Across five years, Intangibles topped out at $14.5 million in Q1 2021 and bottomed at $6.9 million in Q3 2025.
  • Average Intangibles over 5 years is $11.2 million, with a median of $12.0 million recorded in 2022.
  • The sharpest move saw Intangibles decreased 10.49% in 2021, then fell 19.87% in 2025.
  • Year by year, Intangibles stood at $13.2 million in 2021, then fell by 9.64% to $12.0 million in 2022, then fell by 14.21% to $10.3 million in 2023, then decreased by 16.57% to $8.6 million in 2024, then dropped by 19.87% to $6.9 million in 2025.
  • Business Quant data shows Intangibles for ARWR at $6.9 million in Q3 2025, $7.3 million in Q2 2025, and $8.6 million in Q3 2024.